Melfalan Tillomed (Melphalan)

Melphalan works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This interference triggers programmed cell death (apoptosis) in rapidly dividing cancer cells, thereby reducing tumor growth and spread.

The specific dose of Melfalan Tillomed is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, renal and hepatic function, and treatment protocol. Dosing is individualized and should follow the clinician’s written order.

Melphalan is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated in pregnant women and should not be used unless the potential benefit justifies the risk. Breastfeeding is also not recommended, as the drug can be excreted in milk and may harm the infant.

To order Melfalan Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Melphalan belongs to the nitrogen‑mustard alkylating class, similar to cyclophosphamide. Compared with cyclophosphamide, melphalan typically has a higher potency for certain hematologic malignancies but may cause more pronounced myelosuppression. Choice of agent depends on disease type, prior therapy, and individual patient tolerance.

Melfalan Tillomed should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze. Follow standard aseptic techniques when preparing for intravenous infusion.

Melfalan Tillomed is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein under the supervision of qualified healthcare professionals. Infusion rates and pre‑medication (e.g., anti‑emetics) are determined by the treating physician based on the specific protocol.

Serious risks include severe myelosuppression leading to infection, anemia, or bleeding; secondary malignancies such as therapy‑related leukemia; pulmonary toxicity (interstitial pneumonitis); hemorrhagic cystitis; and rare but life‑threatening hypersensitivity reactions. Patients should be monitored closely for signs of infection, respiratory symptoms, and urinary irritation.

Melphalan should be avoided in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in pregnant or nursing women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment, as dose adjustments may be required.